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High-dose chemotherapy with autologous stem cell transplantation (ASCT) remains the standard of care for
patients with multiple myeloma. Outpatient ASCT can be an attractive option given wait times and costs
associatedwith inpatientprocedures.We initiatedanoutpatient transplantationprotocol in2006. Patientswere
treated at a university hospital outpatient clinic that was open 5 days a week. The present study investigated
safety and cost-effectiveness of the outpatient program. Ninety-one patients underwent ASCT between 2006
and 2010. The majority of patients (77%) had Durie-Salmon stage III disease; 38% had 1 or more comorbidities.
Seventy-six patients (84%) were hospitalized during the ﬁrst 100 days, mainly for febrile neutropenia (n ¼ 71).
Overall survival at day 100 was 100%. No patient was admitted to an intensive care unit. Risk factors for pro-
longed hospitalization (longer than 7 days) were disease stage IIB or higher and age>60 years. The cost savings
was $19,522 (Canadian dollars) per patient compared with inpatient ASCT, for an annual savings of approxi-
mately $740,000. In summary, outpatient ASCT performed in a weekday clinic for patients with multiple
myeloma appears to be safe and cost-effective, but is associated with a relatively high hospitalization rate.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION institution, and to evaluate possible cost-effectiveness of the
High-dose chemotherapy with autologous stem cell
transplantation (ASCT) in patients with multiple myeloma
(MM) was ﬁrst reported in 1986 [1]. Although ASCT does not
result in a cure, it is associated with better disease-free
survival and overall survival compared with treatment with
conventional chemotherapy alone [2]. This strategy remains
the standard of care in younger patients, even with the
introduction of new therapeutic agents.
Traditionally, ASCT for patients with MM and other
hematopoietic malignancies has been performed in the
inpatient setting because of the myeloablative nature of the
preparative regimen and concerns for patient safety. With
better understanding of the disease and improvements in
supportive care, initial trials of ASCT in the outpatient setting
were conducted [3-5]. Outpatient ASCT requires the institu-
tion of an interdisciplinary team comprising physicians,
nurses, pharmacologists, nutritionists, and social workers
[6]. The outpatient approach has become particularly
attractive given that many transplantation centers face
chronic bed shortages and ﬁnancial constraints [7,8]. In
addition, MM is considered the most frequent indication for
ASCT in North America and Europe, resulting in considerable
strains on hospital bed availability [9].
The aims of the present study were to analyze the safety
of ASCT in a homogenous cohort of 91 consecutive patients
with MM performed in the outpatient setting at ourdgments on page 551.
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Patients
This study is a retrospective reviewof 91 consecutive adult patients with
MM who underwent outpatient ASCT at our hospital. All patients were
treated on a uniform treatment protocol. Transplantations were performed
between January 2006 and December 2010. Patient outcomes were
recorded during the ﬁrst 100 days posttransplantation. The study was
approved by our hospital’s Institutional Review Board, and all patients
signed informed consents, which allowed data collection and analysis.
Patients were diagnosed with MM and considered eligible for ASCT
according to accepted institutional criteria and guidelines. Most patients
were referred from other centers and received induction chemotherapy at
the discretion of their treating physician. The majority of patients received
vincristine-adriamycine-dexamethasone (VAD)-based chemotherapy.
Patients with either chemotherapy-sensitive disease (with complete
response [CR], very good partial response [VGPR], or partial response [PR]),
as well as those with stable disease (SD) or progressive disease (PD), were
eligible for ASCT.
The pretransplantation workup involved assessment of disease status;
screening for infectious diseases; assessment of cardiac, pulmonary, and
renal function by electrocardiography; multiple gated acquisition scan,
complete pulmonary function studies, and 24-hour urine collection for
creatinine clearance; and screening for other comorbidities as indicated.
Disease status was determined based on the international uniform response
criteria from the International Myeloma Working Group guidelines [10].
Psychiatrists and/or social workers evaluated patients as required. Only
patients with a left ventricular ejection fraction >40% and a corrected lung
CO diffusion capacity of 50% were eligible for ASCT. Outpatient trans-
plantation was offered to patients on a voluntary basis. All patients age <66
years were eligible. Patients age 66-69 years were considered if in good
health. Other requirements were the absence of signiﬁcant comorbidities as
determined by the treating physician, the availability of a caregiver, and
residence close to our center (within a 45-minute drive) or acceptance to
stay at an accommodation close to the hospital. Two lodging facilities, which
are located close to our hospital and run by privately funded volunteerTransplantation.
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caregivers accommodation and meals for a nominal charge. These charges
were covered at no cost to the patient or caregiver either directly or after
application for reimbursement by the patient’s referring institution, or by
the provincial healthcare plan.
Caregivers were adult members of the patient’s family or close friends.
They provided direct assistance to the patient and accompanied the patient
to our outpatient clinic.
Stem Cell Mobilization
Stem cell mobilizationwas performed using cyclophosphamide 1.5 g/m2
i.v. and granulocyte colony-stimulating factor (G-CSF) 5 mg/kg s.c. every 12
hours [11,12]. Grafts were collected by large-volume apheresis using a COBE
Spectra apheresis system (Caridian BCT, Mississauga, Ontario, Canada) as
soon as the peripheral blood CD34þ cell count exceeded 10/mL. A minimum
of 8  106 CD34þ cells/kg were collected, allowing for the possibility of
a second transplantation if required. Grafts were frozen using DMSO 10% in
at least 2 bags and kept in storage at a temperature below 150C in the
vapor phase of nitrogen, as described previously [13].
ASCT Procedure
All patients were assessed and followed at a dedicated outpatient unit,
in close proximity to the hospital’s emergency room and inpatient and
laboratory facilities. No protective isolation besides gloves and a nonsterile
mask were used. The unit was open during weekdays. All treatments and
follow-up assessments were performed in this unit. Medications were
administered via a central venous catheter inserted into the subclavian vein
(a Broviac line inmost cases) [14]. The catheter was inserted on day -3 under
local anesthesia by an experienced radiologist. On day -2, the patient
received high-dose chemotherapy with melphalan (all but 3 patients at
a dose of 200 mg/m2, with 2 receiving 100 mg/m2 and 1 receiving 140/m2).
On day 0, the graft was thawed at the patient’s bedside and infused in the
outpatient unit. A minimum graft of 2  106 CD34þ cells/kg was required.
Patients were followed daily from day -3 to day 0 and consecutively 3 times
weekly thereafter, or more often if required.
Antimicrobiologic Prophylaxis and Treatment
Patients received ciproﬂoxacin 500 mg twice daily from day 0 until
neutrophil engraftment or the initiation of i.v. antibiotics for neutropenic
fever (mainly ceftazidime). For patients seropositive for herpes simplex
virus, prophylaxis with valacyclovir 500 mg daily from day -2 until
neutrophil engraftment was instituted. Patients seropositive for varicella
zoster virus received valacyclovir 500 mg twice daily for up to 3 months
posttransplantation or longer at the discretion of the treating physician.
Antifungal prophylaxis with ﬂuconazole 400 mg/day was started at day
0 and continued until neutrophil engraftment. Pneumocystis jiroveci
prophylaxis with trimethoprim/sulfamethoxazole, 1 double-strength tablet
thrice weekly or twice daily onweekend days, was started after engraftment
and continued for 3 months posttransplantation. In the event of intolerance
or allergy to trimethoprim/sulfamethoxazole, atovaquone or inhaled pent-
amidine was used in some patients.
Other Supportive Measures
G-CSF 5 mg/kg was started in all patients on day þ7 and continued until
neutrophil engraftment. G-CSF was either self-administered or given by
a caregiver or a home care nurse. Packed RBCs were used to maintain
a hemoglobin level >80 g/L, and 5 units of platelets were transfused to
maintain a count <15  109/L. All blood products were leukocyte-depleted,
irradiated, and cytomegalovirus (CMV)-negative (in CMV-negative
patients). Patients received i.v. hydration and electrolyte support in accor-
dance with institutional guidelines.
Hospital Admission
Criteria for admission were uncontrolled nausea and/or vomiting,
inability to eat or swallow tablets related to mucositis, insufﬁcient pain
control, signiﬁcant diarrhea or abdominal cramps, febrile neutropenia, or
judgment of the transplantation physician based on the patient’s clinical
course and performance status.
Engraftment
Neutrophil engraftment after ASCT was deﬁned as the ﬁrst of 3
consecutive days of an absolute neutrophil count exceeding 0.5  109/L.
Platelet recoverywas deﬁned as the ﬁrst of 3 dayswith a blood platelet count
exceeding 20  109/L without transfusion support for 7 consecutive days.
Statistical and Cost Analyses
Clinical data were obtained from a prospectively collected electronic
database and by retrospective chart review. A predeﬁned set of data wascollected. Continuous variables were summarized using mean  standard
deviation and median (range) values; categorical variables are presented as
frequencies and percentages. Associations between hospitalization and
other characteristics were tested using Pearson’s c2 test and Mood’s median
test. The description of follow-up hospitalization was done using 95%
conﬁdence intervals. All analysis were done using SPSS version 15 (IBM,
Armonk, NY), with signiﬁcance set at P < .05. Based on information
provided by our institution for the year 2006 and using the mean number of
hospitalization days, the mean cost of transplantation was computed
separately for both inpatient and outpatient ASCT groups. Charges were
calculated and reported in Canadian dollars (C$).
RESULTS
Patient Characteristics
Between 2006 and 2010,180 patients underwent ASCT for
MMatMaisonneuveRosemontHospital. Ten of these patients
underwent 2 transplantations, resulting in a total of 190
transplant procedures. Ninety-one patients (51%) underwent
ASCT in an outpatient setting and were included in our
analysis. Fifty-three of these patients (58%) were male, and
themedian ageat diagnosiswas56years (range, 34-66 years).
Approximately one-half of the patients had IgG myeloma
(49%) and stage III disease according to the Durie-Salmon
classiﬁcation scheme [15]. Two patients had stage I
myeloma with progressive disease, requiring therapy. Inter-
national Staging System parameters were available for only
48 patients (53%). Creatinine level at diagnosis was <177
mmol/L in 76 patients and 177 mmol/L in 15 patients. The
majorityof patientshadcreatinine and lactatedehydrogenase
valueswithinnormal rangesbeforeundergoingASCT (day-2).
Patient characteristics are summarized inTable 1. Themedian
Eastern Cooperative Oncology Group performance status [16]
at transplantation was 0 (range, 0-2). Thirty-ﬁve patients
(38%) had comorbidities: 17 with 1 comorbidity, 11 with 2
comorbidities, and 7 with 3 comorbidities.
Induction Chemotherapy
The patients underwent a median of 1 course of therapy
(range,1-3) before ASCT.We identiﬁed 15 different schedules
and combinations. In themajority of cases (59%), VAD or VAD
followed by other schedules was used. Eighteen patients
(20%) experienced 10 different complications during induc-
tion therapy, including infectious (n ¼ 9), thromboembolic
(n¼ 4), neuropsychiatric (n¼ 4), and gastrointestinal (n¼ 1)
problems. Twenty-six patients (29%) underwent local
radiotherapy before stem cell mobilization. Forty-two
patients (46%) were treated with bisphosphonates after the
diagnosis of MM.
Response Status at ASCT
The response to induction therapy was evaluated before
stem cell mobilization. Four patients (4%) achieved a strin-
gent CR (sCR), 6 patients (7%) achieved a CR, 8 patients (9%)
achieved a VGPR, and 61 patients (67%) achieved a PR. Eleven
patients proceeded to ASCT without achieving at least a PR.
Nine patients (10%) had SD, and 2 (2%) had PD.
Stem Cell Mobilization and Collection
Stem cell mobilizationwas performed as described above.
Two patients (2%) required a second mobilization attempt.
These patients were remobilized with the same regimen
used previously, with the addition of ancestim (Stemgen;
Amgen, Mississauga, Ontario, Canada) at a dose of 20 mg/kg.
The median number of aphereses was 1 (range, 1-6), and
median CD34þ cell collection was 12.5  106/kg (range,
5-47.5  106/kg).
Table 2
Follow-Up at 100 Days Posttransplantation
Overall survival, n (%) 91 (100)
Patients requiring ICU stay 0
Patients hospitalized, n (%) 76 (84)
95% CI, % 75-90
Time between HSCT and ﬁrst hospitalization (days)
Median (range) 8 (0-16)
Mean  SD 7.50  2.32
95% CI 6.97-8.03
Number of hospitalizations
Median (range) 1 (0-3)
Mean  SD 0.92  0.52
95% CI 0.81-1.03
Total duration of hospitalization, days
Median (range) 8 (0-44)
Mean  SD 9.25  7.64
95% CI 7.66-10.84
SD indicates standard deviation; CI, conﬁdence interval.
Table 1
Patient and Disease Characteristics
Characteristic Value
Number of patients 91
Males, n (%) 53 (58)
Females, n (%) 38 (42)
Year of diagnosis 2004-2009
Age at diagnosis, years, median (range) 56 (34-66)
Type of myeloma, n (%)
Light chain kappa 6 (7)
Light chain lambda 9 (10)
IgG kappa 31 (34)
IgG lambda 14 (15)
IgA kappa 12 (13)
IgA lambda 13 (14)
NS 6 (7)
Durie-Salmon stage, n (%)
IA 2 (2)
IIA 18 (20)
IIB 1 (1)
IIIA 56 (62)
IIIB 14 (15)
International Staging System (ISS) stage, n*
ISS 1 25
ISS 2 12
ISS 3 11
Cytogenetics, ny
del13 1
t(4; 14) 2
Normal 20
Comorbidities, nz
Cardiovascular
Hypertension 17
Coronary heart disease 5
Endocrine
Dyslipidemia 17
Diabetes mellitus 3
Osteoporosis 1
Hypothyroidism 3
Obesity 2
Pulmonary
Chronic obstructive pulmonary disease 2
Rheumatologic
Rheumatoid arthritis 1
Neurologic
Epilepsy 1
Psychiatric 4
Others 4
Creatinine on day-2, mmol/L, median (range) 78 (49-201)
Lactate dehydrogenase on day-2, u/L, median (range) 183 (108-583)
* Available for 48 patients (53%) patients.
y Available for 23 patients (6 only conventional cytogenetic study [ie, no
FISH]).
z Occurring alone or in combination with others. Creatinine normal
values for men 60-120 umol/L for women 45-110 umol/L; LDH normal value
93-210 u/L.
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The median time from diagnosis to ﬁrst ASCT was 229
days (range, 138-1068 days). The median age at ASCT was
57.1 years (range, 36-67 years). Themajority of patients (97%;
n ¼ 88) received melphalan 200 mg/m2 as a preparative
regimen. Three patients received a lower dose of melphalan,
140 mg/m2 in 1 patient and 100 mg/m2 in 2 patients, to
account for diminished renal function. The median CD34þ
cell dose was 7.0  106 cells/kg (range, 2.35-23.6  106/kg).Follow-Up
Table 2 summarizes the frequency, time, duration, and
number of hospitalizations during the ﬁrst 100 days after
ASCT. Seventy-six patients (84%) were hospitalized at
a median of 8 days (range, 0-16 days) after ASCT. The median
duration of hospitalization was 8 days (range, 0-44 days),shorter than that in patients who underwent inpatient ASCT
(median, 28 days).
Neutrophil engraftment occurred in all patients, at
a median of 11 days (range, 8-17 days) post ASCT. Results
were similar in the 15 patients not hospitalized and those
hospitalized after ASCT.
The main causes for hospitalization were neutropenic
fever (n ¼ 71) and mucositis (n ¼ 5). The median severity of
mucositis according to the World Health Organization’s
grading scale [17] was 2 (range, 0-4). In the majority of cases,
microbiological specimens were negative. Clostridium difﬁcile
was isolated in 6 patients. Other pathogens isolated included
Enterococcus (n ¼ 1), Blastocystis hominis (n ¼ 1), and respi-
ratory syncytial virus (n ¼ 1). One patient had Gemella hae-
molysans and Streptococcus mitis septicemia. A review of
radiologic investigations revealed pneumonia in 6 patients,
sinusitis in 1 patient, and diverticulitis in 1 patient.
Risk Factors for Hospitalization
We analyzed patient and disease-related factors that
might affect the hospitalization rate or duration of hospitali-
zation of individual patients. Eastern Cooperative Oncology
Group performance status, number of comorbidities, age at
transplantation (<40, 40-50, 50-60, or >60 years), sex,
number of treatments before ASCT, remission status before
ASCT, time between diagnosis and ASCT, and year of ASCT had
no inﬂuence on hospitalization rate or duration of hospitali-
zation (<7 days versus7 days). Renal function, as measured
by serum creatinine level at diagnosis, with a cutoff value of
177 mmol/L, did not show any statistically signiﬁcant corre-
lationwith hospitalization rate or duration. Neither did renal
function, as measured by serum creatinine and lactate dehy-
drogenase values before the start of the preparative
regimen. An inﬂuence on duration of hospitalization was
observed in patients with advanced disease at diagnosis,
according to the Durie-Salmon staging system. Two-thirds
(68%; 48 of 71) of patients stage IIB or higher were hospital-
ized for longer than 7 days, compared with only 35% (7 of 20)
of patientswith stage IAor IIAdisease (P¼ .008). Furthermore,
the proportion of hospitalizations lasting longer than 7 days
was greater in patients age >60 years compared with those
age <60 years (77% versus 52%; P ¼ .026).
Survival and Remission at Day þ100
All patients were alive at day þ100 after outpatient ASCT.
Response rates at day þ100 based on the International
Myeloma Working Group criteria were as follows: sCR, 11
Table 3
Cost Analysis
Item Inpatient
ASCT
Outpatient
ASCT
Medical visits before ASCT* 637 427
Pretransplantation workup 2031 2031
Mobilization chemotherapy and G-CSF 1171 1171
CD34 measurement 163 163
Stem cell apheresis 1063 1063
Hospitalization 26,069 0
Outpatient ASCT 0 2609
Posttransplantation outpatient carey 737 3921
Rehospitalization/hospitalizationz 5052 9854
Posttransplantation workup 14,402 14,402
Posttransplantation vaccination 104 104
Other direct costs (eg, meals, cleaning,
linen)
1573 558
Indirect costs (eg, administration,
maintenance)
9257 6434
Total costs 62,259 42,737
Effective charges in 2006 Canadian dollars (C$).
* Including laboratory costs, consultations, and physical examinations.
y Up to day þ100.
z Rehospitalization costs for patients undergoing inpatient ASCT; hospi-
talization costs for patients undergoing outpatient ASCT.
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(18%); PR, 27 patients (30%); SD, 3 patients (3%); and PD, 3
patients (3%). Day þ100 data were unavailable for 4 patients.
Cost Analysis
Analysis of costs was based on effective charges in 2006,
provided by the hospital administration. Total costs for an
inpatient ASCT for patients with MM at our institution (in
Canadian dollars) was C$62,259, with a mean duration of
hospitalization of 28 days. For patients who underwent
outpatient ASCT, total costs were C$42,737, including fees for
hospitalization. A detailed cost analysis is presented in
Table 3. The main difference between inpatient and outpa-
tient ASCT costs were higher hospitalization-related costs in
the inpatient group, which offset the costs associated with
the more frequent outpatient visits in the outpatient group.
The cost savings was calculated as C$19,522 per patient,
which, at an average rate of 38 ASCTs per year between 2006
and 2010, resulted in an annual savings of approximately
C$740,000.
DISCUSSION
ASCT remains the most popular treatment modality for
patients with MM. In the current medical and economical
environment, patients desire to take more charge of their
healthcare administration, and appear to favor treatments in
the outpatient settingwhenever feasible. In addition, chronic
bed shortages at many large hematology centers have
prompted physicians and administrators to explore alterna-
tive options for safely treating as many patients as possible
while minimizing delays to transplantation. It is in this
setting that our institution has decided to implement the
possibility of outpatient transplantation for patients with
MM. Patients had to consent and be deemed eligible by their
treating physicians. Obviously, by doing so, a selection bias
has been introduced.
The present study represents a homogenous and
consecutive cohort of patients who underwent outpatient
ASCT. Our ﬁndings demonstrate that outpatient ASCT can be
performed safely (mortality of 0%) in a selected group of
patients. Most patients required admission at some point
during the ﬁrst 100 days posttransplantation, however,especially those patients age>60 years. Patients with disease
stage IIB or higher at diagnosis required longer hospital
stays; however, their duration of hospitalization was still
signiﬁcantly shorter than that for patients who underwent
inpatient ASCT. This shorter in-hospital stay explains the
clear cost advantage of outpatient ASCT.
In a large study by Gertz et al. [6] with 716 patients, 39%
completed the procedure without hospitalization, and the
median duration of hospitalization was 4 days. Patient age
(65 years [n ¼ 537] versus >65 years [n ¼ 177]) and serum
creatinine level (<1.5 mg/dL versus 1.5 mg/dL) were
predictive of the need for hospitalization. Overall 100-day
mortality was 1%. However, in that study, patients also
received prophylactic penicillin and, in cases of fever, i.v.
antibiotics, administered in the outpatient clinic.
Jagannath et al. [3] reported 118 outpatient trans-
plantations in 91 patients, 79% of which were performed on
an outpatient basis. Microbiological prophylaxis differed
from that in our study and included i.v. antibiotics for
patients with mucositis. In addition, patients were provided
with infusion pumps and instructed to self-administer i.v.
antibiotics in the event of febrile neutropenia. Hospital
admission occurred at a median of 8 days after trans-
plantation, similar to our study, and the duration of hospi-
talizationwas also similar. b2-microglobulin (>2.5mg/L) was
the sole risk factor associated with a higher rate of hospi-
talization. A signiﬁcant reduction in costs was reported,
owing mainly to lower hospitalization charges [3].
In the study by Kassar et al. [4], 73% of patients had Durie-
Salmon stage III MM, and 16% received 140 mg/m2
melphalan. More than one-half (58%) of the patients required
hospitalization during the follow-up period. Supportive care
included prophylactic i.v. ceftriaxone at the beginning of
neutropenia in most patients. The majority (80%) of patients
experienced 5 days of neutropenia, and the median dura-
tion of hospitalizationwas 2.16 days. Febrile neutropeniawas
the most frequent cause of hospitalization [4].
Overall, we found a higher rate of hospitalization (84%)
compared with the previous studies (61% [3], 21% [4], and
58% [6]). A major difference between our study and some of
the aforementioned studies was our inclusion of a pop-
ulation with more advanced disease. For example, our pop-
ulation included 77% of patients with Durie-Salmon stage III
disease, compared with only 49% in the study of Jagannath
et al. [3]. This difference might explain our higher hospital-
ization rates, considering that patients with stage IIB or
higher disease at diagnosis were at greater risk for a longer
(>7 days) hospitalization compared with patients with stage
I or IIA MM. In addition, in the previous studies, patients had
access to outpatient care 7 days a week, even 24 hours a day,
compared with our patients, who were managed in
a Monday-Friday day clinic setting. This likely allowed
certain patients to avoid hospitalization, who also could have
been followed in the clinic on weekend days.
In addition, in most of the aforementioned studies,
patients had access to more intensive prophylactic i.v. anti-
biotic regimens. In Arkansas, for example, patients and their
care providers were educated in self-administration of
parenteral antibiotics [3]. At our hospital, febrile neutropenia
is not usuallymanaged in an outpatient setting, although this
approach appears to be safe in selected cases [18]. This may
also explain, at least in part, the higher rate of hospitalization
in our study, given that neutropenic fever was the major
reason for hospital admission. At our hospital, parenteral
antibiotic therapy was continued until resolution of fever
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duration of hospital stay. We further analyzed the cause for
hospitalization and reviewed all microbiological specimens
and radiologic investigations. Interestingly, we found a very
low frequency of positive blood cultures and few patients
with radiologic ﬁndings in our cohort. Kassar at al. [4] found
no source of febrile neutropenia in 66% of their patients.
Our analysis of the cost-effectiveness of outpatient ASCT
compared with inpatient ASCT used data furnished by our
institution, which included not only hospitalization, medical,
and laboratory charges, but also such items as building
maintenance and administrative charges. These data provide
the closest approximation of effective costs incurred by the
hospital. Logically, as is well supported by our data, the
overall costs for inpatient ASCT are higher than those for
outpatient ASCT, given the greater resource requirements
and hospitalization costs associated with inpatient proce-
dures. Labor costs are lower in the outpatient setting, and
accommodation costs are covered by the patients themselves
or are free of charge. Similar to the present study, a retro-
spective Swedish study identiﬁed costs for inpatient care as
themajor contributor to the total costs of MM treatment [19].
Other preliminary studies have suggested that outpatient
ASCT may be associated with signiﬁcantly reduced costs
without compromising patient safety and survival [3,4,20].
The cost savings noted for outpatient ASCT represent
signiﬁcant savings for the Provincial Health Care System.
These funds could be allocated, for example, to help cover the
costs of new drugs to treat MM [21-25].
We had no data with which to compare caregiver-based
costs related to inpatient ASCT and outpatient ASCT. Loss of
income and travel- and meal-related expenses could have
been signiﬁcant in some cases. However, this also could have
been true for patients who resided far from our center
undergoing inpatient ASCT. In some of these cases, family
members had to pay for travel- and accommodation-related
costs by themselves.
All of the patients on this protocol volunteered for
outpatient ASCT. Informal feedback from patients about their
experience has been clearly favorable. Although the majority
of patients required hospitalization at some point, they
preferred to spend as much time as possible outside of the
hospital.
Despite the emergence of newer andmore effective agents
for treating MM, ASCT likely will remain the standard of care
for MM, as either a ﬁrst-line or second-line treatment option,
for some time to come. Thus, it is important to continue to
improve this treatment modality from both medical and
socioeconomic standpoints. Even if new drugs are found to
provide equivalent outcomes, ASCT may still have a role, for
example, in patients living in countries with fewer resources
with restricted availability of new, expensive drugs [26].
In conclusion, outpatient ASCT appears to be safe in
a selected group of patients with MM, with few comorbid-
ities and good performance status in aweekday clinic setting.
These transplantations are cost-effective, related mainly to
shorter hospitalizations, and do not appear to jeopardize
patient outcomes.
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